Valuation: Royalty Pharma plc

Market Cap 30.86B 27.97B 25.87B 23.34B 43.98B 2,910B 45.53B 311B 123B 1,554B 116B 113B 4,934B P/E 2026 *
35.9x
P/E 2027 * 21.2x
Enterprise Value 39.4B 35.71B 33.03B 29.8B 56.15B 3,715B 58.13B 397B 157B 1,985B 148B 145B 6,299B EV / Sales 2026 *
11.2x
EV / Sales 2027 * 10.1x
Free-Float
72.58%
Yield 2026 *
1.5%
Yield 2027 * 1.59%
1 day+0.84%
1 week+2.99%
Current month+3.17%
1 month+17.49%
3 months+18.28%
6 months+29.79%
Current year+79.37%
1 week 66.93
Extreme 66.93
70.37
1 month 59.72
Extreme 59.72
70.37
Current year 38.29
Extreme 38.29
70.37
1 year 37.31
Extreme 37.31
70.37
3 years 24.05
Extreme 24.05
70.37
5 years 24.05
Extreme 24.05
70.37
10 years 24.05
Extreme 24.05
70.37
Manager TitleAgeSince
Chief Executive Officer 62 01/01/1996
Director of Finance/CFO 44 01/01/2010
Chief Tech/Sci/R&D Officer - 21/09/2023
Director TitleAgeSince
Chairman 62 01/04/2020
Director/Board Member 68 11/02/2020
Director/Board Member 63 16/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
06/11/26 Conversion

Executive/Senior Manager

150,000 0.0336%
06/11/26 Conversion

Chief Financial Officer

250,000 0.0560%
04/11/26 Free

Executive/Senior Manager

7,122 0.0016%
Change 5-day change 1-year change 3-year change Capi.($)
+0.84%+2.99%+76.99%+151.85% 30.86B
+1.26%+6.61%+40.79%+136.32% 1,286B
+0.79%+3.45%+45.84%+93.52% 688B
+0.20%+1.28%+26.97%+113.70% 521B
-0.44%+3.69%+41.45%+68.91% 386B
+0.55%+0.70%+59.02%+44.62% 364B
-0.12%+0.74%+28.39%+58.54% 302B
+0.37%+0.37%+3.33%+37.27% 287B
-0.30%+1.14%+38.29%+72.46% 252B
+0.08%+0.71%+34.44%+124.95% 208B
Average +0.32%+2.17%+39.55%+90.21% 433B
Weighted average by Cap. +0.54%+3.25%+37.98%+96.90%

Financials

2026 *2027 *
Net sales 3.52B 3.19B 2.95B 2.66B 5.02B 332B 5.2B 35.48B 14.07B 177B 13.22B 12.94B 563B 3.87B 3.51B 3.25B 2.93B 5.52B 365B 5.71B 39B 15.46B 195B 14.54B 14.23B 619B
Net income 970M 879M 813M 733M 1.38B 91.42B 1.43B 9.76B 3.87B 48.83B 3.64B 3.56B 155B 1.69B 1.54B 1.42B 1.28B 2.42B 160B 2.5B 17.07B 6.77B 85.37B 6.36B 6.23B 271B
Net Debt 8.54B 7.74B 7.16B 6.46B 12.17B 805B 12.6B 85.99B 34.1B 430B 32.05B 31.37B 1,365B 8.43B 7.64B 7.07B 6.38B 12.02B 795B 12.44B 84.91B 33.67B 425B 31.65B 30.98B 1,348B
Projected Income Statement - Annual - Royalty Pharma plc
Logo Royalty Pharma plc
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. It collaborates with innovators from academic institutions, research hospitals and non-profits from small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex's Trikafta and Alyftrek, GSK's Trelegy, Roche's Evrysdi, Johnson & Johnson's Tremfya, Biogen's Tysabri and Spinraza, Servier's Voranigo, AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Pfizer's Nurtec ODT, and Gilead's Trodelvy, and over 17 development-stage product candidates.
Employees
100
Date Price Change Volume
13/11/26 $69.31 +0.49% 2,951,406
12/11/26 $68.97 -1.49% 3,784,552
11/11/26 $70.01 +0.81% 3,532,842
10/11/26 $69.45 +0.99% 3,421,423
09/11/26 $68.77 +2.18% 3,738,136
Trader
Investor
Global
Quality
ESG MSCI
AAA
MarketScreener Ratings - Royalty Pharma plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
69.31USD
Average target price
72.00USD
Spread / Average Target
+3.88%
  1. Stock Market
  2. Stocks
  3. RPRX Stock